Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study

BACKGROUND: Two recombinant enzymes (agalsidase alfa 0.2 mg/kg/every other week and agalsidase beta 1.0 mg/kg/every other week) have been registered for the treatment of Fabry disease (FD), at equal high costs. An independent international initiative compared clinical and biochemical outcomes of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Arends, Maarten, Biegstraaten, Marieke, Wanner, Christoph, Sirrs, Sandra, Mehta, Atul, Elliott, Perry M, Oder, Daniel, Watkinson, Oliver T, Bichet, Daniel G, Khan, Aneal, Iwanochko, Mark, Vaz, Frédéric M, van Kuilenburg, André B P, West, Michael L, Hughes, Derralynn A, Hollak, Carla E M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931248/
https://www.ncbi.nlm.nih.gov/pubmed/29437868
http://dx.doi.org/10.1136/jmedgenet-2017-104863

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931248/
https://www.ncbi.nlm.nih.gov/pubmed/29437868
http://dx.doi.org/10.1136/jmedgenet-2017-104863

Ejemplares similares